



Serum sodium as a predictor to the outcome of critically ill cirrhotic patients

Thesis

Submitted for Fulfilment of Master Degree in Intensive Care
Ain Shams University

By

Ahmed Mohamed Abdelmaguid Serageldin

M.B.B.Ch, Faculty of Medicine, Banha University

Under supervision of

Prof. Sherif Wadie NaShed SergioS

Professor of Anesthesiology, Intensive care and Pain medicine Faculty of Medicine- Ain Shams University

dr. aShraf MahMoud hazeM MohaMed

Assistant Professor of Anesthesiology, Intensive care and Pain medicine Faculty of Medicine- Ain Shams University

dr. heShaM MahMoud haSaN darWeSh

Assistant Professor of Intensive care Theodor BilharzResearch Institute

dr. MarWa ahMed Khairy elbeialy

Lecturer of Anesthesiology ,Intensive care and pain medicine Faculty of Medicine- Ain Shams University 2019



First and foremost, I feel always indebted to *Allah* the most kind and most merciful and we owe to him for his care and guidance in every step in our life.

I wish to express my great attitude and thanks to *Prof. Sherif Wadie Nashed*

Sergios, Professor of Anaesthesia and Intensive Care, Faculty of medicine, Ain Shams University for accepting to supervise this work and for his valuable supervision and guiding comments, he generously devoted much of his precious time and provided unlimited in depth guidance, I sincerely appreciate all the encouragement and support given by him.

Great thanks to *Dr. Ashraf Mahmoud Hazem Mohamed* Assistant Professor of Anesthesiology, Intensive care Faculty of medicine, Ain Shams University and *Dr. Hesham Mahmoud Hasan Darwesh* Assistant Professor of Intensive care

Theodor BilharzResearch Institute, for there great effort ,support and guiding advices .

Iam profound grateful to *DR:Marwa Ahmed Khairy Elbeialy* Lecturer of Anaesthesia and Intensive Care, Faculty of medicine ,Ain Shams University, for her kind and close supervion , constant fatherly advice , support , scientific guidance and her trust in my performance and my work.

Thanks to all the patients who were included in this study and cooperated in this research

Finally thanks to my great family, my wife and my little daughter for there support and encouragement.

List of Contents

| Title | Page No. |
|-----------------------|----------|
| List of abbreviations | I |
| List of Table | III |
| List of figure | IV |
| Introduction | 1 |
| aim of the work | 3 |
| Review of literature | 4 |
| Patients and methods | 43 |
| Results | 50 |
| Discussion | 71 |
| Conclusion | 79 |
| Recommendations | 80 |
| Summary | 81 |
| References | 84 |
| Arabic Summary | 1 |

List Of Abbreviations

| Abbr. | Full term |
|-------|----------------------------------|
| ADH | Antidiuretic hormone |
| AMP | Adenosinemonophosphate |
| AVP | Arginine vasopressin |
| CD | Collecting duct |
| CHF | Congestive heart failure |
| CL | Confidence interval |
| CL- | Chloride |
| CNT | Connecting tubule |
| CPM | Central pontine myelinosis |
| CPS | Child —Pugh score |
| DCT | Distal collecting tubule |
| DH | Dilutional hyponatremia |
| DS | Standard deviation |
| ECF | Extracellular fluid |
| ECFV | Extracellular fluid volume |
| GFR | Glomerular filtration rate |
| HBV | Hepatitis B |
| HCV | Hepatitis V |
| HE | Hepatic encephalopathy |
| HRS | Hepatorenal syndrome |
| HVPG | Hepatic venous pressure gradient |
| ICF | Intracellular fluid |
| INR | International normalized ratio |

| K + | Potassium |
|------------|---|
| LFT | Liver function test |
| Na+ | Sodium |
| NO | Nitrous oxide |
| ODS | Osmotic demyelinating syndrome |
| PH | Portal hypertension |
| PKA | Protein Kinase A |
| RFT | Renal function test |
| SIADH | Syndrome of inappropriate ADH secretion |
| TALH | Thick ascending loop of Henle |
| TIPS | Transjugularintrahepatic portosystemic shunting |
| V2R | Type 2V2 receptor |

List of Teble

| Table | Title | Page No. |
|-------|--|----------|
| 1 | Urine osmolality for differential diagnosis of hyponatremia | 21 |
| 2 | the acid-base and potassium affection by pathogens and drug induced | 25 |
| 3 | Sodium content and ECF distribution of different infusate | 28 |
| 4 | Modified Child —Pugh score(CPS) | 36 |
| 5 | Comparison between both groups regarding age and sex. | 50 |
| 6 | Comparison between both groups regarding Comorbidities | 52 |
| 7 | Comparison between both groups regarding aetiology of liver disease | 53 |
| 8 | Laboratory data among both groups | 55 |
| 9 | frequency of complication among both groups | 58 |
| 10 | Comparison between both groups regarding child Pugh class | 61 |
| 11 | Comparison between the two groups according to the outcome | 63 |
| 12 | correlation between the complications and the mortality in group 1 | 65 |
| 13 | correlation between the complications and the mortality in group 2 | 67 |
| 14 | Comparison between the two groups according to the lactate level. | 69 |
| 15 | correlation between the serum lactate level and the mortality in group 1 | 69 |
| 16 | correlation between the serum lactate level and the mortality in group 2 | 70 |

List of figure

| Fig | Title | Page No. |
|-----|--|----------|
| 1 | Diagnostic approach of hyponatremia | 8 |
| 2 | shows variables that influence renal water handling in healthy Subjects | 13 |
| 3 | proposed mechanism of hypersecretion and systemic effects of vasopressin in cirrhosis with ascites | 14 |
| 4 | Pathogenesis of hyponatremia in cirrhosis | 16 |
| 5 | Age distribution among both groups | 51 |
| 6 | Sex distribution among both groups | 51 |
| 7 | Co morbidities distribution among both groups. | 52 |
| 8 | Albumin level distribution among both groups. | 56 |
| 9 | total bilirubin level distribution among both groups . | 56 |
| 10 | potassium level distribution among both groups. | 57 |
| 11 | complication distribution among both groups. | 59 |
| 12 | presence of Hepato cellular carcinoma (HCC) distribution among both groups. | 59 |
| 13 | jaundice level distribution among both groups. | 60 |
| 14 | Child Pugh score distribution among both groups. | 62 |
| 15 | outcome distribution among both groups. | 63 |
| 16 | correlation between mortality and presence of jaundice. | 66 |
| 17 | correlation between mortality and presence of the hepato renal syndrome. | 68 |
| 18 | correlation between mortality and serum lactate level in group2 | 70 |

Introduction

Cirrhosis is characterized by a progressive circulatory dysfunction, including systemic arterial vasodilatation and reduced peripheral resistance, which induces renal hypo-perfusion. Renal hypo-perfusion represents the stimulus that activates the renin-angiotensin-aldosterone system having sodium and water retention consequence (**Gines and Guevara, 2008**).

Hyponatremia in cirrhosis is defined as serum sodium level below 130 mmol/l. According to this definition, the prevalence of hyponatremia in cirrhotic patients is about 21.6%. If the cut-off limit for serum sodium is considered to be of 135 mmol/l (that represents the lower limit of serum sodium in healthy subjects), the prevalence will reach about 49.4%(Angeli et al,2006).

Cirrhotic hyponatremia is associated with hepatorenal syndrome, jaundice, hepatic encephalopathy and refractory ascites. Serum sodium in cirrhosis that is below 130 mmol/l is associated with a median transplant-free survival of less than 6 months (**Heuman et al,2004**).

Hepatorenal syndrome in cirrhotic patients is characterized by intense stimulation of the renin angiotensin aldosterone system due to an extreme systemic vasodilatation. In this situation, probably, hyponatremia is due to increased levels of arginine vasopressin and to reduced glomerular filtration rate and increased proximal tubular sodium reabsorption (**Gines et al, 2006**).

Several lines of evidence support the existence of a correlation between hyponatremia and hepatic encephalopathy. Levels of serum sodium and ammonia may determine the major electroencephalographic changes in cirrhosis (**Amodio et al, 2001**).

The novel theories suggest that low-grade cerebral oedema which can be induced by hyponatremia may play a part in the pathogenesis of hepatic encephalopathy, This low-grade cerebral oedema resulting from the swelling of astrocytes [maybe by increased intracellular content of glutamine, resulted from ammonia metabolism] is responsible for a number of alterations of the neurological functions, which can lead to hepatic encephalopathy. In this context of the existence of low-grade cerebral oedema, hyponatremia plays an important role in increasing the osmotic pressure on the astrocytes. In this situation, only small increases in ammonia levels can induce clinically manifested hepatic encephalopathy(Haussinger,2006).

Cirrhotic hyponatremia affects the quality of life of the patients because they require a fluid intake restriction in order to prevent further dilution, and is usually not very well tolerated. In a recent study, hyponatremia was an independent predictive factor of the altered quality of life in a patient with cirrhosis (**Konstam et al, 2007**).

In view of the above low serum sodium level in critically ill cirrhotic patients are associated with high complications of liver cirrhosis and inhospital mortality. So we hypothesized that sodium level could be used as a predictor to the outcome of cirrhotic patients who admitted to ICU.

Aim Of Work

The aim of this study is to evaluate the serum sodium levels as a predictor to the outcome of critically ill cirrhotic patients.

SODIUM DISORDERS

Disorders of serum Na⁺ concentration are caused by abnormalities in water homeostasis that lead to changes in the relative ratio of Na⁺ to body water. Water intake and circulating Arginine vasopressin [AVP] constitute the two key effectors in the defense of serum osmolality; defects in one or both of these defense mechanisms cause most cases of hyponatremia and hypernatremia.

Notably, volume status also modulates the release of AVP by the posterior pituitary so that hypovolemia is associated with higher circulating levels of the hormone at each level of serum osmolality. Similarly, in hypervolemia causes of arterial underfilling, e.g., heart failure and cirrhosis, the associated neurohumoral activation is associated with an increase in circulating AVP, leading to water retention and hyponatremia. Therefore, a key concept in sodium disorders is that the absolute plasma Na⁺ concentration tells one nothing about the volume status of a specific patient; this must be taken into account in the diagnostic and therapeutic approach (Verbalis, 2011).

HYPONATREMIA: AN OVERVIEW

Hyponatremia is an electrolyte disturbance in which the sodium concentration in the serum is lower than normal. Hyponatremia is defined as aplasma Na⁺ concentration <135mEq/L (**Adrogué and Madias, 2005; David et al, 2012**).

Hyponatremia is a very common disorder, occurring in hospitalized patients. This disorder is almost always the result of an increase in circulating AVP and/or increased renal sensitivity to AVP, combined with any intake of free water. Hyponatremia can therefore occur by an

increase in Total Body Water [TBW], a decrease in body solutes (either Na^+ or K^+), or any combination of these. In most cases, more than one of these mechanisms is operant (**Schrier et al, 2013**)

CLASSIFICATION OF HYPONATREMIA

An assessment of Extracellular Fluid [ECF] volume provides a useful working classification of Hyponatremia as it can be associated with decreased, normal, or high total body sodium (**Parikh et al,2007**). So it can be classified into:

- (1) Hyponatremia with ECF volume depletion.
- (2) Hyponatremia with excess ECF volume.
- (3) Hyponatremia with normal ECF volume.

HYPOVOLEMIC HYPONATREMIA

Hypovolemia causes marked neurohumoral activation, increasing circulating levels of AVP. The increase in circulating AVP helps preserve blood pressure via vascular and baroreceptor VIA receptors and increases water reabsorption via renal V2 receptors; activation of V2 receptors can lead to hyponatremia in the setting of increased free-water intake (Adrogué and Madias, 2000).

Non-renal causes of hypovolemic hyponatremia include gastrointestinal (GI) loss (vomiting, diarrhea, tube drainage and insensible loss (sweating, burns) of Na⁺-CI⁻ and water in the absence of adequate oral replacement; urine Na⁺ concentration is typically <20 mEq/L. Notably, these patients may be clinically classified as euvolemic, with only the reduced urinary Na⁺ concentration to indicate the cause of their hyponatremia (**Verbalis and Berl, 2008**).

The renal causes of hypovolemic hyponatremia share an inappropriate loss of Na⁺-Cl⁻ in the urine, leading to volume depletion and an increase in circulating AVP; urine Na⁺ concentration is typically >20 mEq/L. A deficiency in the circulating aldosterone and/or its renal effects can lead to hyponatremia in primary adrenal insufficiency and other causes of hypoaldosteronism; hyperkalemia and hyponatremia in a hypotensive and/or hypovolemic patient with high urine Na⁺ concentration (>20 mEq/L) should strongly suggest this diagnosis. (Milionis et al, 2002)

Salt-losing nephropathies may lead to hyponatremia when sodium intake is reduced due to impaired renal tubular function. Typical causes include reflux nephropathy, interstitial nephropathies, post-obstructive uropathy, medullary cystic disease, and the recovery phase of acute tubular necrosis .(Milionis et al, 2002).

HYPERVOLEMIC HYPONATREMIA (Dilutional hyponatremia)

Patients with hypervolemic hyponatremia develop an increase in total body Na⁺-Cl⁻ that is accompanied by a proportionately greater increase in total body water exceeds that of Na⁺, leading to a reduced plasma Na⁺ concentration.

As in hypovolemic hyponatremia, the causative disorders can be separated by the effect on urine Na⁺ concentration, with acute or chronic renal failure uniquely associated with an increase in urine Na⁺ concentration. With exception to renal failure, these states are characterized by sodium retention(urinary Na⁺ concentration<10 mEq/L) (Verbalis, 2011).

EUVOLEMIC HYPONATREMIA

Patients and experimental animals with hypothyroidism often have impaired water excretion and sometimes develop hyponatremia. The dilution defect is reversed by treatment with thyroid hormones. Both decreased delivery of filtrate to the diluting segment and persistent secretion of AVP, alone or combination, have been proposed as mechanisms responsible for the defect (**Sterns et al, 2009**).

Severe hyponatremia also can be a consequence of secondary due to pituitary disease; (Schrier, 2006; Schrier et al,2006) whereas the deficit in circulating aldosterone in primary adrenal insufficiency causes hypovolemic hyponatremia, the predominant glucocorticoid deficiency in secondary adrenal failure is associated with euvolemic hyponatremia (Diederich et al,2003; Olchovsky et al, 2005).

Glucocorticoids exert a negative feedback on AVP release by the posterior pituitary so that hydrocortisone replacement in the patients will rapidly normalize the AVP response to osmolality, reducing circulating AVP.

The syndrome of inappropriate antidiuresis is the most common cause of euvolemic hyponatremia(Palmer et al 2003).

DIAGNOSIS OF HYPONATREMIA

Figure 1 illustrates the outline of diagnostic approach of hyponatremia




Figure 1: Diagnostic approach of hyponatremia (Verbalis, 2011).

HYPONATREMIA IN CIRRHOSIS

Hyponatremia is a frequent complication of advanced cirrhosis related to an impairment in the renal capacity to eliminate solute-free water that causes a retention of water that is disproportionate to the retention of sodium ,thus causing a reduction in serum sodium concentration and hypo-osmolality (Angeli et al, 2006).